Workflow
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA
NMRANeumora Therapeutics(NMRA) Prnewswire·2025-02-20 14:56

Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, particularly related to its experimental depression treatment, navacaprant [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding 50,000inNeumora′sIPOareencouragedtocontactthefirmtodiscusstheirlegaloptions[1].Group2:AllegationsAgainstNeumora−ThecomplaintallegesthatNeumoraanditsexecutivesviolatedfederalsecuritieslawsbymakingfalsestatementsandfailingtodisclosecriticalinformationaboutthePhaseTwoandPhaseThreeclinicaltrials[4].−SpecificallegationsincludetheamendmentoftrialinclusioncriteriatoshowstatisticallysignificantresultsandthelackofadequatedatainthePhaseTwoTrials,whichaffectedthepredictabilityofthePhaseIIIstudyresults[4].Group3:ImpactonStockPerformance−FollowingtheannouncementofthefailureofnavacaprantinthePhaseIIIKoastal−1trial,Neumora′sstockpricedroppedby8150,000 in Neumora's IPO are encouraged to contact the firm to discuss their legal options [1]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about the Phase Two and Phase Three clinical trials [4]. - Specific allegations include the amendment of trial inclusion criteria to show statistically significant results and the lack of adequate data in the Phase Two Trials, which affected the predictability of the Phase III study results [4]. Group 3: Impact on Stock Performance - Following the announcement of the failure of navacaprant in the Phase III Koastal-1 trial, Neumora's stock price dropped by 81%, closing at 1.97 per share on January 2, 2025 [5].